Dennis J. Slamon

APLA Health — United States

Medicine · Health Sciences

126h-index99.4kcitations985works8.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(368), Monoclonal and Polyclonal Antibodies Research(223), Advanced Breast Cancer Therapies(215), Cancer Treatment and Pharmacology(93), Lung Cancer Research Studies(84)

Publications983 total

Supplemental Table 4 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
2025Open Access
Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Supplemental Table 3 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
2025Open Access
Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Supplemental Methods 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
ESMO Open·2025· 9 citedOpen Access
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer
Targeted Oncology·2025Open Access
P2.02.16 Identification of Deruxtecan-Induced Methylome Signature in NSCLC Cell Lines
Journal of Thoracic Oncology·2025
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ <i>ERBB2</i> -Negative Early Breast Cancer
JAMA Oncology·2025· 6 citedOpen Access
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence
Journal of Clinical Oncology·2025· 1 cited
369P Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in estrogen receptor-positive early breast cancer patients. A pooled analysis from GEICAM and TRIO trials
Annals of Oncology·2025
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials
The Oncologist·2025Open Access
Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer
International Journal of Gynecological Cancer·2025· 2 citedOpen Access
page 1 of 50Next →

Frequent Co-authors

Michael F. Press(10), Mark D. Pegram(9), Richard S. Finn(8), Miguel Martín(6), Seock‐Ah Im(5), Nadia Harbeck(5), Melody Cobleigh(4), Charles Ginther(4), Richard J. Pietras(4), Axel Ullrich(3), Steven Shak(3), Karen A. Gelmon(3), Charles L. Vogel(3), Debu Tripathy(3), Nicholas J. Robert(3), John Crown(3), Igor Bondarenko(3), Sherene Loi(3), Cynthia Huang Bartlett(3), Judy Dering(3)